1. Peptides

Teriparatide (Synonyms: PTH 1-34; hPTH (1-34); Human parathyroid hormone-(1-34))

Cat. No.: HY-P0059 Purity: 99.92%
Handling Instructions

Teriparatide is a PHT agonist, with an IC50 of 2 nM in HEK293 cells. Sequence: Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Teriparatide Chemical Structure

Teriparatide Chemical Structure

CAS No. : 52232-67-4

Size Price Stock Quantity
10 mM * 1 mL in Water USD 457 In-stock
Stock in the United States
Estimated Time of Arrival: December 31
1 mg USD 120 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
5 mg USD 180 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
10 mg USD 252 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
50 mg USD 504 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
100 mg USD 744 In-stock
Stock in the United States
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Teriparatide is a PHT agonist, with an IC50 of 2 nM in HEK293 cells. Sequence: Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe.

IC50 & Target

IC50: 2 nM (PTH)[1].

In Vivo

Trabecular bone calcium and dry weight of the distal femur increased significantly in Teriparatide-treated animals. The increase in trabecular calcium compared with vehicle control occurred as early as 1 week after initiation of treatment with a 35% and 45% increase, respectively, for 10 μg/kg and 40 μg/kg Teriparatide. Similar results were observed for trabecular dry weight. After 4 weeks of treatment with 10 mg/kg or 40 mg/kg Teriparatide, trabecular calcium increased significantly by 70% and 123%, respectively, compared with the vehicle and by 73%[1].
The 4-week Teriparatide administration increase the pore ratio, number, and density as well as the cortical area, thickness, and bone mineral content (BMC), without significant influencing the volumetric bone mineral density (BMD). The 4-week Teriparatide administration + 8-week vehicle administration decrease the pore ratio, number, and density as well as the cortical area and thickness, compared with the 4-week Teriparatide administration, but the pore ratio, cortical area, and thickness are still higher compared with the 12-week vehicle administration. The 4-week Teriparatide administration + 8-week higherdose IBN administration increase the cortical area, thickness, BMC, and volumetric BMD and decrease the pore ratio, but not the pore number or density, compared with the 4-week Teriparatide administration + 8-week vehicle administration[2].

Clinical Trial
Solvent & Solubility
In Vitro: 

H2O : ≥ 50 mg/mL (12.14 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.2429 mL 1.2143 mL 2.4285 mL
5 mM 0.0486 mL 0.2429 mL 0.4857 mL
10 mM 0.0243 mL 0.1214 mL 0.2429 mL
*Please refer to the solubility information to select the appropriate solvent.
References
Animal Administration
[1][2]

Rats[1]
Teriparatide is administered daily to 4-week-old male rats for 1, 2, or 4 weeks with different concentrations (10, 40 μg/kg). At each time point, longitudinal growth, expressed as maximal femur length, is not statistically different between treated and control rats or between the two different treatment groups. Midfemur diaphyseal widths also do not differ between groups[1].
Rabbits[2]
Forty-two female New Zealand white rabbits (17-21 weeks old) are used throughout the study. After 10 days of adaptation to their new environment, the rabbits (18-22 weeks old) are randomized into six groups of 7 animals each using the stratified weight method, as follows: 4-week vehicle administration group (4W-Veh), 4-week Teriparatide (TPTD) administration group (4W-Teriparatide: 20 μg/kg, subcutaneously [s.c.], daily), 12-week vehicle administration group (12W-Veh), 4-week Teriparatide administration + 8-week vehicle administration group (4W-Teriparatide + 8W-Veh), 4-week Teriparatide administration + 8-week lower-dose IBN administration group (4W-Teriparatide + 8W-IBN(L): 20 μg/kg of IBN, s.c., every 4 weeks), and 4-week Teriparatide administration + 8-week higher-dose IBN administration group (4W-Teriparatide + 8W-IBN(H): 100 μg/kg of IBN, s.c., every 4 weeks)[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

4117.72

Formula

C₁₈₁H₂₉₁N₅₅O₅₁S₂

CAS No.

52232-67-4

Storage
Powder -80°C 2 years
  -20°C 1 year
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Teriparatide
Cat. No.:
HY-P0059
Quantity:

Teriparatide

Cat. No.: HY-P0059